PharmaShots | Incisive News in 3 Shots

Subscribe Now

Tubulis

Tubulis Reports the US FDA’s Fast Track Designation of TUB-040 to Treat Ovarian Cancer

Tubulis Reports the US FDA’s Fast Track Designation of TUB-040 to Treat Ovarian Cancer

June 28, 2024

Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-aa

Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-aa

June 20, 2024

Tubulis Entered into a License Agreement with BMS to Develop ADCs Therapies for the Treatment of Cancer

Tubulis Entered into a License Agreement with BMS to Develop ADCs Therapies for the Treatment of Cancer

April 20, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us